Randomized, Double-Blind, Placebo-Controlled Crossover Trials of Venlafaxine for Hot Flashes After Breast Cancer

CME Activity Information
Release Date:	January 16, 2007
Most Recent Review:	January 16, 2007*
Most Recent Update:	January 16, 2007
Date Credit Expires:	January 16, 2009
Time to Complete:	1 hour
Medium:	Internet Online
*Click here to learn more about our review process.

Instructions for Participation

1. Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
2. Study the educational activity
3. Complete the CME quiz and evaluation
4. After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

   *The CME quiz and evaluation must be completed by January 16, 2009, in order to receive the credit or participation certificate.

1. Discuss the efficacy of venlafaxine in alleviating hot flashes and improving secondary outcomes.
2. Identify the week of treatment that venlafaxine was most effective.
3. List three side effects associated with venlafaxine.

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process: http://theoncologist.alphamedpress.org/misc/ifora.shtml. All manuscripts are reviewed by the Editorial Board with ad hoc assistance from two or more external experts in the field. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Credentials: Indiana University, Indianapolis, Indiana, USA. Telephone: 317-278-6093; Fax: 317-274-2021; E-mail: carpentj{at}iupui.edu.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Wyeth's Venlafaxine XR for the treatment of hot flashes. The author has also served as a consultant for UFI's biolog hot flash monitor.

Credentials: Indiana University, Indianapolis, Indiana, USA.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Wyeth's Venlafaxine XR for the treatment of hot flashes.

Shelley Johns, Psy.D.

Credentials: Indiana University, Indianapolis, Indiana, USA.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Wyeth's Venlafaxine XR for the treatment of hot flashes.

Patrick O. Monahan, Ph.D.

Credentials: Indiana University, Indianapolis, Indiana, USA.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Wyeth's Venlafaxine XR for the treatment of hot flashes.

Faouzi Azzouz, Ph.D.

Credentials: Indiana University, Indianapolis, Indiana, USA.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Wyeth's Venlafaxine XR for the treatment of hot flashes.

Julie L. Elam, M.S.N., R.N.

Credentials: Indiana University, Indianapolis, Indiana, USA.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Wyeth's Venlafaxine XR for the treatment of hot flashes.

Cynthia S. Johnson, M.A.

Credentials: Indiana University, Indianapolis, Indiana, USA.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Wyeth's Venlafaxine XR for the treatment of hot flashes.

Richard C. Shelton, M.D.

Credentials: Vanderbilt University, Nashville, Tennessee, USA.
Disclosures: The author has indicated that they discuss the unlabeled, investigational, or alternative use(s) of Wyeth's Venlafaxine XR for the treatment of hot flashes. The author has received research support from Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutica, Pfizer, Roehn-Polenc-Rorer Pharmaceutica, sanofi-aventis, Wyeth-Ayerst Laboratories, AstraZeneca, and Abbott Laboratories. The author has served as a consultant for Pfizer and Janssen Pharmaceutica. The author has also served on the Speaker's Bureau at Bristol-Myers Squibb, Eli Lilly, Janssen Pharmaceutica, Pfizer, GlaxoSmithKline, Solvay Pharmaceuticals, Wyeth-Ayerst Laboratories, and Abbott Laboratories.

• Take this course